dvdres-dec-2017-00190-Supplementary_File – Supplemental material for Elevated levels of insulin-like growth factor-binding protein 1 predict outcome after acute myocardial infarction: A long-term follow-up of the glucose tolerance in patients with acute myocardial infarction (GAMI) cohort

<p>Supplemental material, dvdres-dec-2017-00190-Supplementary_File for Elevated levels of insulin-like growth factor-binding protein 1 predict outcome after acute myocardial infarction: A long-term follow-up of the glucose tolerance in patients with acute myocardial infarction (GAMI) cohort by Viveca Ritsinger, Kerstin Brismar, Linda Mellbin, Per Näsman, Lars Rydén, Stefan Söderberg and Anna Norhammar in Diabetes & Vascular Disease Research</p

Biomarkers related to smoking and gender of MI patients and non-MI subjects.

<p>Significance of the differences calculated with Mann-Whitney´s U test.</p><p>Biomarkers related to smoking and gender of MI patients and non-MI subjects.</p

Median and interquartile range (IQR) of pro- and active forms of MMP-8 between MI patients and non-MI subjects.

<p>au = arbitrary unit.</p><p>Median and interquartile range (IQR) of pro- and active forms of MMP-8 between MI patients and non-MI subjects.</p

Biomarkers related to smoking and gender of MI patients and non-MI subjects.

<p>Significance of the differences calculated with Mann-Whitney´s U test.</p><p>Biomarkers related to smoking and gender of MI patients and non-MI subjects.</p

Characteristics of the study population.

<p>ACEI = angiotensin-converting enzyme inhibitors, IQR = Interquartile range, BOP = bleeding on probing, PPD = probing pocket depth. Significance of the differences calculated with Students t-test (age), Chi 2 or Mann-Whitney´s U test.</p><p>Characteristics of the study population.</p

The mean levels of MMP-8, -9, MPO, TIMP-1 and the ratios of MMP-8 and -9/TIMP-1 in stimulated saliva from MI and non-MI subjects.

<p><i>p</i>1 indicates significance of the differences after a bivariate comparison. <i>p</i>2 indicates the significance after compensation for differences in smoking, BOP, PPD 4–5 mm and PPD ≥ 6 mm.</p><p>The mean levels of MMP-8, -9, MPO, TIMP-1 and the ratios of MMP-8 and -9/TIMP-1 in stimulated saliva from MI and non-MI subjects.</p

Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial

Objectives. To assess whether the use of cardioprotective therapies for type 2 diabetes varies by gender and whether the risk of cardiovascular events is higher in women versus men in the REWIND trial, including an international type 2 diabetes patient population with a wide range of baseline risk. Design. Gender differences in baseline characteristics, cardioprotective therapy, and the achieved clinical targets at baseline and two years were analyzed. Hazards for cardiovascular outcomes (fatal/nonfatal stroke, fatal/nonfatal myocardial infarction, cardiovascular death, all-cause mortality, and heart failure hospitalization), in women versus men were analyzed using two Cox proportional hazard models, adjusted for randomized treatment and key baseline characteristics respectively. Time-to-event analyses were performed in subgroups with or without history of cardiovascular disease using Cox proportional hazards models that included gender, subgroup, randomized treatment, and gender-by-subgroup interactions. Results. Of 9901 participants, 46.3% were women. Significantly fewer women than men had a cardiovascular disease history. Although most women met treatment targets for blood pressure (96.7%) and lipids (72.8%), fewer women than men met the target for cardioprotective therapies at baseline and after two years, particularly those with prior cardiovascular disease, who used less renin-angiotensin-aldosterone system inhibitors, statins, and aspirin than men. Despite these differences, women had lower hazards than men for all outcomes except stroke. No significant gender and cardiovascular disease history interactions were identified for cardiovascular outcomes. Conclusions. In REWIND, most women met clinically relevant treatment targets, but in lower proportions than men. Women had a lower risk for all cardiovascular outcomes except stroke. Clinical trials.gov registration number: NCT01394952</p

TaqMan assay standard curve plot (left) and amplification plot (right): For miRNA copy number quantification; standard curve was prepared from ten time dilutions of recombinant plasmid containing hcmv-miR-UL112-3p amplicon as insert, which was used as a template in TaqMan miRNA assays.

<p>TaqMan assay standard curve plot (left) and amplification plot (right): For miRNA copy number quantification; standard curve was prepared from ten time dilutions of recombinant plasmid containing hcmv-miR-UL112-3p amplicon as insert, which was used as a template in TaqMan miRNA assays.</p

Patient characteristics and summarised results.

<p>Patient characteristics and summarised results.</p

The prevalence of hcmv-miR-UL112-3p was determined using a TaqMan miRNA assay, and the seroprevalence of IgG and IgM against HCMV was detected with ELISA assays in all patients and controls.

<p>HC = Healthy Controls, GBM = Glioblastoma multiforme, RA = Rheumatoid Arthritis and DM = Diabetes Mellitus (patients from the DIGAMI-2 cohort).</p